Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets
Exicure, Inc. has entered into an agreement to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for approximately US$4.8 million.
Filings · News reference
Exicure, Inc. announced it has filed a Form 12b-25 with the SEC to delay the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Exicure, Inc. has entered into an agreement to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for approximately US$4.8 million.
Exicure announced the sale of its GPC-100 (burixafor) program assets to South Korean company GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion). The transaction includes clinical data, intellectual property, and related materials from the Phase 2 clinical trial completed in January 2026. GPCRT will assume future milestone and royalty obligations, while Exicure retains liabilities incurred before September 1, 2026. The sale is part of Exicure's strategic alternatives evaluation to maximize stockholder value.
Filed: 2026-11-10 AccNo: 0001193125-26-455339 Size: 854 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
As previously disclosed, on June 5, 2026, Nasdaq notified the Company that it did not satisfy Nasdaq Listing Rule 5550(b)(1), which requires a listed company to maintain a minimum of $2.5 million in stockholders’
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.